EARLY-ONSET COLORECTAL CANCER

DELPHI INITIATIVE RECOMMENDATIONS ON EO-CRC (DIRECT): THE PATH TO IMPROVE DIAGNOSIS AND CLINICAL MANAGEMENT

ORGANIZED BY
Gastroenterology and Gastrointestinal Endoscopy Unit, Vita-Salute San Raffaele University
San Raffaele Scientific Institute - Milan, Italy
and
FONDAZIONE INTERNAZIONALE MENARINI

1st-2nd September 2022 | Venue: Sala L. Pirelli – Via Clerici, 5 - Milano
WITH THE ENDORSEMENT OF
Società Italiana di Gastroenterologia (SIGE)

PRESIDENT OF THE MEETING
Giulia Martina Cavestro
M.D. Ph.D. Gastroenterology and Gastrointestinal Endoscopy Unit
Vita-Salute San Raffaele University, San Raffaele Scientific Institute, Milan, Italy

CO-PRESIDENTS OF THE MEETING
Gabriela Möselein
President “European Hereditary Tumour Group” (EHTG)
Cristina Oliani
President “Associazione Italiana Familiarità Ereditarietà Tumori” (AIFET)
Swati G. Patel
President “The Collaborative Group of the Americas on Inherited Gastrointestinal Cancer” (CGA-IGC)

SCIENTIFIC SECRETARIAT
Marta Puzzono
Gastroenterology and Gastrointestinal Endoscopy Unit, Vita-Salute San Raffaele University, San Raffaele Scientific Institute, Milan, IT
Alessandro Mannucci
Gastroenterology and Gastrointestinal Endoscopy Unit, Vita-Salute San Raffaele University, San Raffaele Scientific Institute, Milan, IT

CO-ORGANIZING BY
Fondazione Internazionale Menarini
Centro Direzionale Milanofiori
20089 Rozzano (Milan, Italy) | Edificio L – Strada 6
Phone: +39 02 55308110 | Fax: +39 02 55305739
E-mail: milan@fondazione-menarini.it | www.fondazione-menarini.it

ORGANIZING SECRETARIAT
AVEC S.r.l. - Incentive Paintings
Via Lavoratori Autobianchi, 1
c/o Polo Tecnologico Brianza - Edificio 9 - Ufficio 14
20832 Desio (MB, Italy)
Phone: +39 0362 581579 - Fax: +39 0362 1860074
E-mail: angela.volpe@avec-eventi.com - info@avec-eventi.com

LOGISTIC SECRETARIAT
AIM ITALY SRL
Via G. Ripamonti, 129 - 20141 Milan (Italy)
tel 02.566011 / mail: info.aimeducation@aimgroup.eu
The incidence of colorectal cancer before the age of 50 is increasing. Patients with early-onset colorectal cancer (eoCRC) are managed according to CRC guidelines that are not specific for this age group. A multidisciplinary international group (DIRECt) was convened to develop the first evidence-based consensus recommendations for the management of eoCRC. The DIRECt group produced 28 statements in 7 areas of interest: diagnosis, screening, genetics, pathology-oncology, endoscopy, therapy, and end-stage disease. These are the first evidence-based consensus recommendations on eoCRC.
# PROGRAMME

**THURSDAY, 1st SEPTEMBER 2022**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30 a.m.</td>
<td>G. M. Cavestro (Milan, IT) S. G. Patel (Aurora, USA) C. Oliani (Rovigo, IT) G. Möslein (Duisburg, DE) S. Danese (Milan, IT) Fondazione Internazionale Menarini Welcome greetings</td>
</tr>
<tr>
<td>09.00 a.m.</td>
<td><strong>SESSION I – DIAGNOSIS OF eoCRC</strong></td>
</tr>
<tr>
<td>09.00 a.m.</td>
<td>Moderators:</td>
</tr>
<tr>
<td></td>
<td>M. B. Yurgelun (Boston, USA)</td>
</tr>
<tr>
<td></td>
<td>A. Cercek (New York, USA)</td>
</tr>
<tr>
<td></td>
<td>C. Eng (Nashville, USA)</td>
</tr>
<tr>
<td>09.00 a.m.</td>
<td>C. Murphy (Houston, USA)</td>
</tr>
<tr>
<td>09.20 a.m.</td>
<td>What is the global epidemiology and age cut-off to define eoCRC?</td>
</tr>
<tr>
<td>09.20 a.m.</td>
<td>Summary from the “DIRECT” recommendations and update from the last-year literature</td>
</tr>
<tr>
<td>09.20 a.m.</td>
<td>S. Kupfer (Chicago, USA)</td>
</tr>
<tr>
<td>09.40 a.m.</td>
<td>Which symptoms and clinical signs prompt evaluation for eoCRC?</td>
</tr>
<tr>
<td>09.40 a.m.</td>
<td>Summary from the “DIRECT” recommendations and update from the last-year literature</td>
</tr>
<tr>
<td>09.40 a.m.</td>
<td>S. G. Patel (Aurora, USA)</td>
</tr>
<tr>
<td>10.00 a.m.</td>
<td>Which test(s) and what should be the time frame for evaluation of symptoms</td>
</tr>
<tr>
<td>10.00 a.m.</td>
<td>and signs of eoCRC? Summary from the “DIRECT” recommendations and</td>
</tr>
<tr>
<td>10.00 a.m.</td>
<td>update from the last-year literature</td>
</tr>
<tr>
<td>10.00 a.m.</td>
<td>Panel Discussion</td>
</tr>
<tr>
<td>10.20 a.m.</td>
<td>Coffee break</td>
</tr>
</tbody>
</table>
## SESSSION II – eCRC SCREENING

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker/Panel</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.50 a.m.</td>
<td>A. Latchford</td>
<td>Should population screening for CRC begin before the age of 50?</td>
</tr>
<tr>
<td>11.05 a.m.</td>
<td>E. Stoffel</td>
<td>PROS</td>
</tr>
<tr>
<td>11.20 a.m.</td>
<td>E. Dekker</td>
<td>CONS</td>
</tr>
<tr>
<td>11.20 a.m.</td>
<td>M. De Los Angeles Daca-Alvarez</td>
<td>How can family history influence in eoCRC detection? What other risk factors in assessing an individual’s risk for eoCRC? Summary from the “DIRECT” recommendations and update from the last-year literature</td>
</tr>
<tr>
<td>11.40 a.m.</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>12.00 p.m.</td>
<td>L. Lachi</td>
<td>INTRODUCTION</td>
</tr>
<tr>
<td>12.00 p.m.</td>
<td>C. R. Boland</td>
<td>LECTURE</td>
</tr>
<tr>
<td>12.30 p.m.</td>
<td>Lunch</td>
<td></td>
</tr>
</tbody>
</table>
### THURSDAY, 1st SEPTEMBER 2022

#### SESSION III – GENETICS OF eoCRC

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>02.00 p.m.</td>
<td><strong>M. Dominguez Valentin</strong> (Oslo, NO)</td>
<td>Who should receive germline genetic testing among eoCRC patients, and when should this take place? Summary from the “DIRECT” recommendations and update from the last-year literature. How do polygenic risk scores have the potential to impact eoCRC in the future? Summary from the “DIRECT” recommendations and update from the last-year literature.</td>
</tr>
<tr>
<td>02.30 p.m.</td>
<td><strong>H. Hampel</strong> (Duarte, USA)</td>
<td>What genes should/could be included in germline multi-gene panel tests for eoCRC patients? Summary from the “DIRECT” recommendations and update from the last-year literature.</td>
</tr>
<tr>
<td>02.50 p.m.</td>
<td><strong>F. Kastrinos</strong> (New York, USA)</td>
<td>Could risk assessment tools be helpful for eoCRC patients? Summary from the “DIRECT” recommendations and update from the last-year literature.</td>
</tr>
<tr>
<td>03.10 p.m.</td>
<td></td>
<td>Panel Discussion</td>
</tr>
<tr>
<td>03.30 p.m.</td>
<td></td>
<td><em>Coffee break</em></td>
</tr>
<tr>
<td>Time</td>
<td>Speaker</td>
<td>Topic</td>
</tr>
<tr>
<td>-------------</td>
<td>----------------------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>04.00 p.m.</td>
<td>E. Vilar (Houston, USA)</td>
<td>Demetra Project</td>
</tr>
<tr>
<td>04.15 p.m.</td>
<td>M. Puzzono (Milan, IT)</td>
<td>PLSD update</td>
</tr>
<tr>
<td>04.30 p.m.</td>
<td>S. K. Singh (Boston, USA)</td>
<td>Artificial intelligence relates to endoscopy for eoCRC diagnosis</td>
</tr>
<tr>
<td>04.45 p.m.</td>
<td>D. Winter (Dublin, IR)</td>
<td>The “REACCT Collaborative”</td>
</tr>
<tr>
<td>05.15 p.m.</td>
<td>E. Meldolesi (Rome, IT)</td>
<td>Artificial intelligence and OMICS integration on tumor response and clinical outcomes’ prediction in eoCRC patients</td>
</tr>
<tr>
<td>05.30 p.m.</td>
<td>T. Buffart (Amsterdam, NL)</td>
<td>Towards improved treatment strategies of early onset CRC</td>
</tr>
<tr>
<td>05.45 p.m.</td>
<td>A. Mannucci (Milan, IT)</td>
<td>Refining the age of CRC screening</td>
</tr>
<tr>
<td>06.00 p.m.</td>
<td>Gianluca Mauri (Milan, IT)</td>
<td>IANG-CRC study: an integrative omics approach to decipher mechanisms of cancer immunoediting as candidate targets of new therapies for eoCRC</td>
</tr>
</tbody>
</table>
**PROGRAMME**

**FRIDAY, 2nd SEPTEMBER 2022**

**SESSION V– eoCRC ONCOLOGICAL PATH**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00 a.m. - 08.10 a.m.</td>
<td><strong>G. M. Cavestro</strong> (Milan, IT) <strong>G. Möslein</strong> (Duisburg, DE) <strong>C. Oliani</strong> (Rovigo, IT) <strong>S. G. Patel</strong> (Aurora, USA)</td>
<td>Welcome greetings</td>
</tr>
<tr>
<td>08.10 a.m. - 08.20 a.m.</td>
<td><strong>V. Valentini</strong> (Rome, IT) <strong>R. Cannizzaro</strong> (Aviano, IT) <strong>S. Siena</strong> (Milan, IT)</td>
<td><strong>S. Cascinu</strong> (Milan, IT) How to decide adjuvant postoperative treatment. Summary from the “DIRECT” recommendations and update from the last-year literature</td>
</tr>
<tr>
<td>08.20 a.m. - 08.40 a.m.</td>
<td><strong>E. Meldolesi</strong> (Rome, IT)</td>
<td>How to decide neoadjuvant treatment in eoCRC? Who to give it to and what to give? Summary from the “DIRECT” recommendations and update from the last-year literature</td>
</tr>
<tr>
<td>08.40 a.m. - 09.00 a.m.</td>
<td></td>
<td>Panel Discussion</td>
</tr>
</tbody>
</table>
# SESSION VI – eoCRC PERSONALIZED MEDICINE

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00 a.m.</td>
<td>A. Remo (Verona, IT)</td>
<td>Is immunohistochemistry/molecular microsatellite analysis for mismatch repair proteins necessary in eoCRC endoscopic biopsies? Molecular markers for selection of targeted treatments in patients with eoCRC. Summary from the “DIRECT” recommendations and update from the last-year literature</td>
</tr>
<tr>
<td>09.20 a.m.</td>
<td>V. S. Vanni (Milan, IT)</td>
<td>Which criteria to select patients for fertility preservation and which information needs to be provided to preserve fertility and fecundity before and after treatment? Summary from the “DIRECT” recommendations and update from the last-year literature</td>
</tr>
<tr>
<td>09.40 a.m.</td>
<td></td>
<td>Panel Discussion</td>
</tr>
<tr>
<td>10.00 a.m.</td>
<td></td>
<td>Coffee Break</td>
</tr>
</tbody>
</table>
## SESSION VII – eoCRC SURGICAL PATH

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.20 a.m.</td>
<td>T. Seppala (Helsinki, FI)</td>
<td>What diagnostic workup for eoCRC before surgical treatment? Summary from the “DIRECT” recommendations and update from the last-year literature</td>
</tr>
<tr>
<td>10.40 a.m.</td>
<td>G. Möslein (Duisburg, DE)</td>
<td>What modifications to surgical approach can be offered? Summary from the “DIRECT” recommendations and update from the last-year literature</td>
</tr>
<tr>
<td>11.00 a.m.</td>
<td>Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>
FRIDAY, 2nd SEPTEMBER 2022

SESSION VIII – EoCRC ENDOSCOPIC PATH

Moderators:

C. A. Burke (Cleveland, USA)
D. Liska (Cleveland, USA)
K. Monahan (London, UK)

11.20 a.m. - 11.40 p.m.

E. Stoffel (Ann Arbor, USA)
What endoscopic technologies, standard quality metrics and follow-up schedule for eoCRC being treated either endoscopically or surgically? Summary from the “DIRECT” recommendations and update from the last-year literature

11.40 p.m. - 12.00 p.m.

E. Dekker (Amsterdam, NL)
Is there a place for endoscopic therapy of T1 cancers in patient with eoCRC? Summary from the “DIRECT” recommendations and update from the last-year literature

12.00 p.m. - 12.20 p.m.

Panel Discussion

12.20 p.m. - 01.00 p.m.

INTRODUCTION
S. Siena (Milan, IT)

LECTURE
A. Bardelli (Turin, IT)
“Adaptive Evolution: How Bacteria and Cancer Cells Survive Stressful Conditions and Drug Treatment”

01.00 p.m. - 02.00 p.m.

Lunch break
### SESSION IX – LIFE DURING END-STAGE DISEASE IN eoCRC

**Moderators:**
- R. Caccialanza (Pavia, IT)
- C. Oliani (Rovigo, IT)
- K. Ng (Boston, USA)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>02.30 p.m.</td>
<td>A. Sartore Bianchi (Milan, IT)</td>
<td>Management of cancer-related symptoms in eoCRC, including pain, fatigue, nausea, vomiting, constipation, diarrhea and cachexia? Summary from the “DIRECT” recommendations and update from the last-year literature</td>
</tr>
<tr>
<td>02.50 p.m.</td>
<td>C. I. Ripamonti (Milan, IT)</td>
<td>How should supportive care programs be organized, for the better care of patients with eoCRC? Summary from the “DIRECT” recommendations and update from the last-year literature</td>
</tr>
<tr>
<td>03.10 p.m.</td>
<td></td>
<td>Panel Discussion</td>
</tr>
</tbody>
</table>

### SESSION X – PATIENT PERSPECTIVES IN eoCRC

**Moderators:**
- F. Kühn (Munich, DE)
- A. Malesci (Milan, IT)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>03.30 p.m.</td>
<td>Z. Maravic (Bruxelles, BE)</td>
<td>eoCRC: EU patients’ perspective and engagement</td>
</tr>
<tr>
<td>03.40 p.m.</td>
<td>C. Borassi (Port Chester, USA)</td>
<td>eoCRC: US patients’ perspective and engagement</td>
</tr>
<tr>
<td>03.50 p.m.</td>
<td></td>
<td>Panel Discussion</td>
</tr>
<tr>
<td>04.20 p.m.</td>
<td></td>
<td>Closing remarks</td>
</tr>
<tr>
<td>Name</td>
<td>Institution</td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Alberto Bardelli</td>
<td>Department of Oncology, University of Torino Candiolo, IT</td>
<td></td>
</tr>
<tr>
<td>Clement Richard Boland</td>
<td>University of California San Diego School of Medicine San Diego, USA</td>
<td></td>
</tr>
<tr>
<td>Cindy Borassi</td>
<td>Colon Cancer Foundation Port Chester, USA</td>
<td></td>
</tr>
<tr>
<td>Randall E. Brand</td>
<td>Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Pittsburgh, USA</td>
<td></td>
</tr>
<tr>
<td>Chiara Brombin</td>
<td>University Centre for Statistics in the Biomedical Sciences Vita-Salute San Raffaele University Milan, IT</td>
<td></td>
</tr>
<tr>
<td>Tineke Buffart</td>
<td>Department of Medical Oncology Amsterdam UMC, NL</td>
<td></td>
</tr>
<tr>
<td>Carol A Burke</td>
<td>Sanford R. Weiss, MD Center for Hereditary Colorectal Neoplasia, Digestive Disease and Surgery Institute Cleveland Clinic, USA</td>
<td></td>
</tr>
<tr>
<td>Riccardo Caccialanza</td>
<td>Clinical Nutrition and Dietetics Unit, Fondazione IRCCS Policlinico San Matteo Pavia, IT</td>
<td></td>
</tr>
<tr>
<td>Renato Cannizzaro</td>
<td>Division of Oncological Gastroenterology, Centro di Riferimento Oncologico di Aviano (CRO), IT</td>
<td></td>
</tr>
<tr>
<td>Stefano Cascinu</td>
<td>Oncology Unit, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, IT</td>
<td></td>
</tr>
<tr>
<td>Andrea Cercek</td>
<td>Memorial Sloan Kettering Cancer Center New York, USA</td>
<td></td>
</tr>
<tr>
<td>Silvio Danese</td>
<td>Gastroenterology and Gastrointestinal Endoscopy Unit, Vita-Salute San Raffaele Scientific Institute Milan, IT</td>
<td></td>
</tr>
<tr>
<td>Evelien Dekker</td>
<td>Gastroenterology and Hepatology, Amsterdam University Medical Centers, NL</td>
<td></td>
</tr>
<tr>
<td>Maria De Los Angeles Daca-Alvarez</td>
<td>Department of Gastroenterology, Hospital Clínico de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, ES</td>
<td></td>
</tr>
<tr>
<td>Mev Dominguez Valentín</td>
<td>Department of Tumour Biology, The Norwegian Radium Hospital, Oslo University Hospital, NO</td>
<td></td>
</tr>
<tr>
<td>Cathy Eng</td>
<td>Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA; Vanderbilt-Ingram Cancer Center, USA</td>
<td></td>
</tr>
</tbody>
</table>
FACULTY

Ajay Goel  
Center for Translational Genomics and Oncology, Baylor Scott & White Research Institute and Charles A. Sammons Cancer Center  
Dallas, USA

José Gaston Guillem  
University of North Carolina  
Chapel Hill, USA

Heather Hampel  
City of Hope  
Duarte, USA

Charles Kahi  
Gastroenterology, Indiana University Medical Center  
Indianapolis, USA

Matthew F Kalady  
Division of Colon and Rectal Surgery, The Ohio State University Wexner Medical Center  
Columbus, USA

Fay Kastrinos  
Division of Digestive and Liver Diseases, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center and the Vagelos College of Physicians and Surgeons  
New York, USA

Florian Kühn  
Head Colorectal Cancer Center, Department of Surgery, University Hospital of Munich, DE

Sonia Kupfer  
Section of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Chicago, USA

Luigi Laghi  
Department of Medicine and Surgery, University of Parma, IT

Andrew Latchford  
The Polyposis Registry, St Mark’s Hospital, London North West University Healthcare NHS Trust  
London, UK

David Liska  
Department of Colorectal Surgery, Digestive Disease & Surgery Institute, Cleveland Clinic, USA

Patrick Lynch  
Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center  
Houston, USA

Alberto Malesci  
Gastroenterology and Gastrointestinal Endoscopy Unit  
Vita-Salute San Raffaele University, San Raffaele Scientific Institute, Milan, IT

Gianluca Mauri  
Department of Hematology, Oncology, and Molecular Medicine, and Niguarda Cancer Center Grande Ospedale Metropolitano Niguarda, Milan, IT

Alessandro Mannucci  
Gastroenterology and Gastrointestinal Endoscopy Unit, Vita-Salute San Raffaele University, San Raffaele Scientific Institute  
Milan, IT

Zorana Maravic  
Digestive Cancers Europe  
Bruxelles, BE
Elisa Meldolesi
Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, UOC di Radioterapia, Oncologica, Fondazione Policlinico Universitario A. Gemelli, IRCCS
Rome, IT

Pål Møller
Department of Tumor Biology, Institute of Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, NO

Kevin Monahan
Imperial College London and The Family History of Bowel Cancer Clinic, Department of Gastroenterology, West Middlesex University Hospital, Chelsea and Westminster Hospitals NHS Trust
London, UK

Gabriela Möslein
Department of Surgery, Ev. Krankenhaus Bethesda Hospital
Duisburg, DE

Caitlin C. Murphy
University of Texas Health Science Center at Houston (UTHealth) School of Public Health, USA

Kimmie Ng
Gastrointestinal Cancer Center, Young-Onset Colorectal Cancer Center, Harvard Medical School Dana Farber Cancer Institute
Boston, USA

Cristina Oliani
Ambulatorio Familiarita’ Neoplastica UOC Oncologia medica ULSS5 Polesana
Rovigo, IT

Swati G. Patel
Division of Gastroenterology & Hepatology, University of Colorado Anschutz School of Medicine, Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, Colorado, USA

Marta Puzzono
Gastroenterology and Gastrointestinal Endoscopy Unit, Vita-Salute San Raffaele University, San Raffaele Scientific Institute
Milan, IT

Andrea Remo
Pathology Unit, ULSS9 “Scaligera”, Ospedale “Orlandi” Verona, IT

Carla Ida Ripamonti
Oncology Supportive Care in Cancer Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT

Andrea Sartore-Bianchi
Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, IT

Toni Seppala
Department of Gastrointestinal Surgery, Helsinki University Central Hospital, FI

Salvatore Siena
Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, IT

Satish K Singh
Department of Medicine, Section of Gastroenterology, VA Boston Healthcare System, USA
<table>
<thead>
<tr>
<th>FACULTY</th>
</tr>
</thead>
</table>
| **Zsokia K. Stadler**  
Department of Medicine,  
Memorial Sloan Kettering Cancer Center  
New York, USA |
| **Eduardo Vilar-Sanchez**  
Department of Clinical Cancer Prevention,  
The University of Texas MD Anderson Cancer Center  
Houston, USA |
| **Peter P. Stanich**  
Division of Gastroenterology, Hepatology & Nutrition, The Ohio State University  
Wexner Medical Center  
Columbus, USA |
| **Desmond Winter**  
University College Dublin, School of Medicine, St Vincent’s Hospital Elm Park  
Dublin, IR |
| **Elena Stoffel**  
Division of Gastroenterology, Department of Internal Medicine, University of Michigan, USA |
| **Matthew B. Yurgelun**  
Brigham and Women’s Hospital, Harvard Medical School, Dana Farber Cancer Institute  
Boston, USA |
| **Sapna Syngal**  
Brigham and Women’s Hospital, Harvard Medical School, Dana Farber Cancer Institute  
Boston, USA |
| **Emanuele Urso**  
Clinica Chirurgica 1, Dip di Scienze Oncologiche e Chirurgiche, Azienda Ospedaliera Università di Padua, IT |
| **Vincenzo Valentini**  
Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia  
UOC di Radioterapia, Oncologica, Fondazione Policlinico Universitario A. Gemelli, IRCCS Rome, IT |
| **Valeria Stella Vanni**  
Obstetrics and Gynaecology Unit, Fertility Centre, Obstetrics and Gynaecology Unit, IRCCS San Raffaele Scientific Institute  
Milan, IT |
In accordance with the current Covid regulations, we would like to remind you that the number of places reserved is limited to the actual capacity of the venue. We therefore kindly ask you to cancel your registration if you are unable to attend, so that other interested users can participate.

Further to specific requests of the hospitality structures you are strongly advised to come equipped with the EU Digital Covid Certificate in order to ensure your participation in all phases of the Congress.
HOW TO REGISTER AND JOIN THE EVENT

LIVE STREAMING
Via website www.en.fondazione-menarini.it

IF YOU ARE ALREADY A SUBSCRIBER TO THE FONDAZIONE MENARINI RESERVED AREA
1) Please visit the page of the congress of your interest:
   www.en.fondazione-menarini.it
2) Click on “SUBSCRIBE TO LIVE STREAMING” and LOG IN with your credentials, check the Privacy Notice
   and click on “ATTEND”.
You can enjoy the LIVE STREAMING for free on 1st and 2nd September 2022.

IF YOU ARE NOT YET A SUBSCRIBER, REGISTER FOR FREE IN THE FONDAZIONE MENARINI RESERVED AREA
1) Go to www.en.fondazione-menarini.it and click on “Register” (home page, on the right).
2) To register in the reserved area, just fill in the form, available here:
   www.en.fondazione-menarini.it
3) Fill in all the mandatory fields and complete the registration, click on REGISTER (only once).
   Wait for the confirmation page to appear, do not click on anything or leave the page.
   Once you receive confirmation, return to the home page, you will already be logged-in to the reserved area.
4) Visit the page of the congress of your interest:
   www.en.fondazione-menarini.it
5) Confirm your registration by clicking on “SUBSCRIBE TO LIVE STREAMING”, check the Privacy Notice and
   click on “ATTEND”.
You can enjoy the LIVE STREAMING for free on 1st and 2nd September 2022.

If you need more help, please feel free to contact us, click here:
www.en.fondazione-menarini.it/Home>Contact-Us
HOW TO REGISTER AND JOIN THE EVENT

VIA FONDAZIONE MENARINI APP
Download the APP of Fondazione Menarini, click here or scan the QR CODE:
www.en.fondazione-menarini.it/download-App-Fondazione-Menarini

LIVE STREAMING
IF YOU ARE ALREADY A SUBSCRIPER TO THE FONDAZIONE MENARINI RESERVED AREA
You can access the APP with the same username and password that you use in the website. Visit the page of the event and confirm your participation, click on “SUBSCRIBE TO LIVE STREAMING”.
You can enjoy the LIVE STREAMING for free on 1st and 2nd September 2022.

IF YOU ARE NOT YET A SUBSCRIPER, REGISTER FOR FREE IN THE FONDAZIONE MENARINI RESERVED AREA
Click on the profile icon in the top right-hand corner, or in the details of an event. Click on LOGIN:
Click on the red button REGISTER; to register in the reserved area, just fill in all the mandatory fields of the form.
Now it is necessary to log in with your username (email) and password! Then click on LOGIN.
Now you are logged-in to the APP (you will see your name near the user icon).
You can visit the schedule of the event, and click on the red button “SUBSCRIBE TO LIVE STREAMING”, check the Privacy Notice and the confirm.
You can enjoy the LIVE STREAMING for free on 1st and 2nd September 2022.

RESIDENTIAL EVENT
IF YOU ARE ALREADY A SUBSCRIPER TO THE FONDAZIONE MENARINI RESERVED AREA
You can access the APP with the same username and password that you use on the website. Visit the page of the event and confirm your participation, click on “SUBSCRIBE TO RESIDENTIAL EVENT”.
You will be redirected to the Fondazione Menarini website, please follow the instructions above for RESIDENTIAL EVENT.

IF YOU ARE NOT YET A SUBSCRIPER, REGISTER FOR FREE IN THE FONDAZIONE MENARINI RESERVED AREA
Click on the profile icon in the top right-hand corner, or in the details of an event. Click on LOGIN:
Click on the red button REGISTER; to register in the reserved area, just fill in all the mandatory fields of the form.
Now it is necessary to log in with your username (email) and password! Then click on LOGIN.
Now you are logged-in to the APP (you will see your name near the user icon).
You can visit the schedule of the event by clicking on the red button “SUBSCRIBE TO RESIDENTIAL EVENT”
You will be redirected to the Fondazione Menarini website, please follow the instructions above for RESIDENTIAL EVENT.

If you need more help, please feel free to contact us, click here:
www.en.fondazione-menarini.it/Home/Contact-Us
GENERAL INFORMATION

MEETING VENUE
Sala L. Pirelli - Via Clerici 5 - Milan, Italy

SECRETARIAT DURING THE MEETING
The Secretariat will be open at the following times:
Thursday, 1st September: 8.00 a.m. - 6.15 p.m.
Friday, 2nd September: 7.30 a.m. - 4.20 p.m.

OFFICIAL LANGUAGE
The official language of the Meeting will be English.

TECHNICAL FACILITIES
Facilities will be available for computer presentations and overhead projections.
A business center with PC (Powerpoint for Windows) will be available for check and preview of presentations. It is essential that speakers take their presentation to the business center at least one hour before the session starts.

The center will be open at the following times:
Thursday, 1st September: 8.00 a.m. - 6.15 p.m.
Friday, 2nd September: 7.30 a.m. - 4.20 p.m.

LUNCHES AND COFFEE BREAKS
Lunches and coffee breaks will be served in the Meeting area.

We would like to remind you that the number of places reserved is limited to the actual capacity of the venue. We therefore kindly ask you to cancel your registration if you are unable to attend, so that other interested users can participate. Further to specific requests of the hospitality structures you are strongly advised to come equipped with the EU Digital Covid Certificate in order to ensure you participation in all phases of the Congress.